Showing 11-20 of 333 grants
Title | Institution | Researcher | Program | Duration | Total Award Amount |
---|---|---|---|---|---|
Immune tolerance technology for islet transplantation | Wayne State University | Zhiqiang Cao | Cures | 01-July-2023 to 30-June-2025 | $199,231.00 |
Orally Delivered Glucose-Responsive Insulin | Wayne State University | Zhiqiang Cao | Improving Lives | 01-June-2024 to 31-May-2026 | $274,499.13 |
Ketone Monitoring in T1D: Effect of SGLT2i during Usual Care and with Insulin Deficiency | Washington University | Janet McGill | Improving Lives | 01-September-2022 to 31-August-2024 | $359,651.69 |
Enhancing Human Stem Cell-Derived Islet Survival and Function Using SA-PD-L1-Presenting Microgels | Washington University | Jeffrey Millman | Cures | 01-August-2024 to 31-July-2027 | $1,125,000.00 |
Genetic Engineering to Improve Engraftment of Stem Cell-Derived Islets | Washington University | Jeffrey Millman | Cures | 01-February-2023 to 31-January-2026 | $450,000.00 |
Assess the antigenic profile in human T1D: from β-cell crinophagy to peripheral blood | Washington University | Xiaoxiao Wan | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
Combining Arteriovenous Bundle and ECM-Based Biomaterial Technologies to Induce Potent Neovascularization Following Islet Transplantation | Wake Forest University Health Sciences | Giuseppe Orlando | Cures | 01-April-2025 to 31-March-2026 | $248,692.00 |
Developing Fit-For-Purpose Patient-reported Outcomes (PRO) Measure(s) in Type 1 Diabetes | Vector Psychometric Group | R. J. Wirth | Cures | 01-February-2025 to 31-March-2027 | $797,087.00 |
Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234,766.00 |
Bcl6 and the B/Tfh axis in type 1 diabetes pathogenesis | Vanderbilt University Medical Center (VUMC) | Dudley McNitt | Cures | 01-March-2024 to 28-February-2027 | $265,320.00 |